Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by Rosmorducon Jun 19, 2020 11:00am

122 Views

Post# 31169275

RE:RE:RE:RE:Buying opportunity

I believe in the product based on the history and studies I have read but the way management is handling this is unreal.

Every time there is a press release, we end up with more questions without having answers to all our previous questions going back 6 months.

Jeeez. You need to have a strong stomach and a strong conviction as a shareholder in this company.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023